These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
299 related items for PubMed ID: 6265426
1. N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics. Hanslo D, King A, Shannon K, Warren C, Phillips I. J Antimicrob Chemother; 1981 Jun; 7(6):607-17. PubMed ID: 6265426 [No Abstract] [Full Text] [Related]
2. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance. Brown JE, Del Bene VE, Collins CD. Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986 [Abstract] [Full Text] [Related]
4. In vitro comparative activity of moxalactam, GR 20263, and N-formimidoyl thienamycin to other beta-lactam antibiotics and tobramycin against enterobacteriaceae and staphylococci. Cynamon MH, Granato PA. Chemotherapy; 1982 Feb; 28(3):204-8. PubMed ID: 6212205 [Abstract] [Full Text] [Related]
5. In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime. Verbist L, Verhaegen J. Antimicrob Agents Chemother; 1981 Mar; 19(3):402-6. PubMed ID: 6264844 [Abstract] [Full Text] [Related]
6. Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin. Braveny I, Machka K, Elsser R. Infection; 1982 Jan; 10(1):45-9. PubMed ID: 6279523 [Abstract] [Full Text] [Related]
7. Susceptibility of gram-positive cocci to various antibiotics, including cefotaxime, moxalactam, and N-formimidoyl thienamycin. Cherubin CE, Corrado ML, Sierra MF, Gombert ME, Shulman M. Antimicrob Agents Chemother; 1981 Oct; 20(4):553-5. PubMed ID: 6282200 [Abstract] [Full Text] [Related]
8. In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria. Pusztai-Markos Z, Pranada F. Eur J Clin Microbiol; 1982 Feb; 1(1):49-51. PubMed ID: 6293811 [Abstract] [Full Text] [Related]
9. Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin. Owens WE, Finegold SM. Antimicrob Agents Chemother; 1983 Apr; 23(4):626-9. PubMed ID: 6305265 [Abstract] [Full Text] [Related]
10. In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp. Nasu M, Maskell JP, Williams RJ, Williams JD. Antimicrob Agents Chemother; 1981 Oct; 20(4):433-6. PubMed ID: 6282191 [Abstract] [Full Text] [Related]
11. In-vitro activity and beta-lactamase stability of Sch 29482, a penem antibiotic. Comparisons with ceftazidime and moxalactam. Dornbusch K, Adamsson L, Gezelius L, Hallander H. J Antimicrob Chemother; 1982 Feb; 9 Suppl C():113-21. PubMed ID: 6460739 [No Abstract] [Full Text] [Related]
12. Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria. Borobio MV, Aznar J, Jimenez R, Garcia F, Perea EJ. Antimicrob Agents Chemother; 1980 Feb; 17(2):129-31. PubMed ID: 6247966 [Abstract] [Full Text] [Related]
13. In vitro evaluation of LY127935 (6050S) compared with cefotaxime, eight other beta-lactams and two aminoglycosides. Barry AL, Thornsberry C, Jones RN. J Antimicrob Chemother; 1980 Nov; 6(6):775-84. PubMed ID: 6254942 [No Abstract] [Full Text] [Related]
14. Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods. O'Donnell ED, Freimer EH, Gilardi GL, Raeder R. Antimicrob Agents Chemother; 1982 Apr; 21(4):673-5. PubMed ID: 6211143 [Abstract] [Full Text] [Related]
15. Antibacterial activity of moxalactam (LY-127935) compared with cefotaxime and other beta-lactam antibiotics against clinical isolates of enterobacteriacea and non-fermenters. Verbist L. Arzneimittelforschung; 1981 Apr; 31(6):982-6. PubMed ID: 6266430 [Abstract] [Full Text] [Related]
16. In-vitro activity of MK0787 (N-formimidoyl thienamycin) against Pseudomonas aeruginosa and other Gram-negative organisms and its stability to their beta-lactamases. Livermore DM, Williams RJ, Williams JD. J Antimicrob Chemother; 1981 Nov; 8(5):355-62. PubMed ID: 6798011 [No Abstract] [Full Text] [Related]
17. The comparative activities of N-formimidoyl theinamycin (MK0787), moxalactam, cefotaxime and cefoperazone against Yersinia enterocolitica and Listeria monocytogenes. Ahonkhai VI, Sierra MF, Cherubin CE, Shulman MA. J Antimicrob Chemother; 1982 May; 9(5):411-2. PubMed ID: 6284696 [No Abstract] [Full Text] [Related]
18. A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives. Cullmann W, Opferkuch W, Stieglitz M, Werkmeister U. Antimicrob Agents Chemother; 1982 Aug; 22(2):302-7. PubMed ID: 6821459 [Abstract] [Full Text] [Related]
19. Effect of N-formimidoyl thienamycin (MK0787) on beta-lactamases and activity against beta-lactamase-producing strains. Toda M, Sato K, Nakazawa H, Inoue M, Mitsuhashi S. Antimicrob Agents Chemother; 1980 Nov; 18(5):837-8. PubMed ID: 6969580 [Abstract] [Full Text] [Related]
20. Comparative activity of N-formimidoyl thienamycin with third generation cephalosporins and ureido penicillins against multiple resistant Serratia marcescens. Miller MA, LeFrock JL, Vercler MJ. Microbiol Immunol; 1981 Nov; 25(11):1119-27. PubMed ID: 6276701 [Abstract] [Full Text] [Related] Page: [Next] [New Search]